Concizumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 90 publications

Transforming Hemophilia Treatment With Novel Rebalancing Agents: Clinical Studies and Practical Perspectives.

Transforming Hemophilia Treatment With Novel Rebalancing Agents: Clinical Studies and Practical Perspectives.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: September 03, 2026

New and novel pharmacotherapies for hemophilia A: an update.

New and novel pharmacotherapies for hemophilia A: an update.

Journal: Expert opinion on pharmacotherapy

Published: August 20, 2026

Advances in treatments for hemophilia A/B with inhibitors: current treatment gaps and promising therapies.

Advances in treatments for hemophilia A/B with inhibitors: current treatment gaps and promising therapies.

Journal: Expert review of hematology

Published: July 08, 2026

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Journal: Thrombosis and haemostasis

Published: June 30, 2026

The Tissue Factor-TFPI Pathway as a Therapeutic Target in Bleeding Disorders of Unknown Cause.

The Tissue Factor-TFPI Pathway as a Therapeutic Target in Bleeding Disorders of Unknown Cause.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 20, 2026

Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report.

Concizumab prophylaxis in a 2-year-old patient with severe hemophilia B and inhibitor: a case report.

Journal: Frontiers in pharmacology

Published: May 08, 2026

Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.

Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 28, 2026

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.

Journal: The Cochrane database of systematic reviews

Published: March 24, 2026

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Comparative Efficacy and Safety of Non-Clotting Factor Prophylaxis Versus. on-Demand Therapy in Hemophilia: A Meta-Analysis of Randomized Controlled Trials.

Journal: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Published: March 03, 2026

Real-World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort.

Real-World Effectiveness and Safety of Concizumab Prophylaxis in Hemophilia: Results From a National French Cohort.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: February 25, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

Showing 1-12 of 90

Last Updated: 09/26/2026